(Q51034646)

English

Social phobia: the clinical efficacy and tolerability of the monoamine oxidase -A and serotonin uptake inhibitor brofaromine. A double-blind placebo-controlled study.

scientific article published in November 1995

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

27 March 2018

http://europepmc.org/abstract/MED/8619339

Social phobia: the clinical efficacy and tolerability of the monoamine oxidase -A and serotonin uptake inhibitor brofaromine. A double-blind placebo-controlled study. (English)

1 reference

Europe PubMed Central

27 March 2018

http://europepmc.org/abstract/MED/8619339

0 references

1 reference

based on heuristic

inferred from title

4

1 reference

Europe PubMed Central

27 March 2018

http://europepmc.org/abstract/MED/8619339

author name string

Fahlén T

1

1 reference

Europe PubMed Central

27 March 2018

http://europepmc.org/abstract/MED/8619339

Nilsson HL

2

1 reference

Europe PubMed Central

27 March 2018

http://europepmc.org/abstract/MED/8619339

Borg K

3

1 reference

Europe PubMed Central

27 March 2018

http://europepmc.org/abstract/MED/8619339

Pauli U

5

1 reference

Europe PubMed Central

27 March 2018

http://europepmc.org/abstract/MED/8619339

language of work or name

0 references

publication date

1 November 1995

1 reference

Europe PubMed Central

27 March 2018

http://europepmc.org/abstract/MED/8619339

Acta Psychiatrica Scandinavica

1 reference

Europe PubMed Central

27 March 2018

http://europepmc.org/abstract/MED/8619339

92

1 reference

Europe PubMed Central

27 March 2018

http://europepmc.org/abstract/MED/8619339

351-358

1 reference

Europe PubMed Central

27 March 2018

http://europepmc.org/abstract/MED/8619339

5

1 reference

Europe PubMed Central

27 March 2018

http://europepmc.org/abstract/MED/8619339

Social phobia. Review of a neglected anxiety disorder

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1995.TB09596.X

21 January 2018

Social phobia. Comorbidity and morbidity in an epidemiologic sample

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1995.TB09596.X

21 January 2018

Relationship of social phobia with other psychiatric illness

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1995.TB09596.X

21 January 2018

Syndrome comorbidity in patients with major depression or dysthymia: prevalence and temporal relationships

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1995.TB09596.X

21 January 2018

Prevalence and comorbidity of dysthymic disorder among psychiatric outpatients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1995.TB09596.X

21 January 2018

Psychiatric comorbidity in patients with generalized anxiety disorder.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1995.TB09596.X

21 January 2018

DSM-III-R generalized anxiety disorder in the National Comorbidity Survey.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1995.TB09596.X

21 January 2018

Social-Evaluative Anxiety in Panic Disorder and Agoraphobia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1995.TB09596.X

21 January 2018

Phenelzine vs atenolol in social phobia. A placebo-controlled comparison

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1995.TB09596.X

21 January 2018

Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1995.TB09596.X

21 January 2018

Treatment of social phobia with clonazepam and placebo.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1995.TB09596.X

21 January 2018

The monoamine oxidase inhibiting properties of CGP 11305 A.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1995.TB09596.X

21 January 2018

A Canadian multicentre placebo-controlled study of a fixed dose of brofaromine, a reversible selective MAO-A inhibitor, in the treatment of major depression.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1995.TB09596.X

21 January 2018

Development of a Rating Scale for Primary Depressive Illness

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1995.TB09596.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1995.TB09596.X

21 January 2018

The assessment of anxiety states by rating

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1995.TB09596.X

21 January 2018

The Hopkins Symptom Checklist (HSCL)--factors derived from the HSCL-90.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1995.TB09596.X

21 January 2018

The physiology and psychology of behavioral inhibition in children.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1995.TB09596.X

21 January 2018

Identifiers

10.1111/J.1600-0447.1995.TB09596.X

1 reference

Europe PubMed Central

27 March 2018

http://europepmc.org/abstract/MED/8619339

1 reference

Europe PubMed Central

27 March 2018

http://europepmc.org/abstract/MED/8619339

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51034646&oldid=1526129466"